Collection of Samples From Patients With MDS
NCT03072498 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 24
Last updated 2019-03-26
Summary
The purpose of this study is to collect information and bone marrow, blood, saliva, cheek cells and skin to be used in the laboratory to assist the sponsor in identifying a new way of treating MDS.
Conditions
- Myelodysplastic Syndromes(MDS)
Sponsors & Collaborators
-
University of California, San Diego
collaborator OTHER -
PersImmune, Inc
lead INDUSTRY
Principal Investigators
-
Rafael Bejar, MD · UCSD
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-04-06
- Primary Completion
- 2020-12-05
- Completion
- 2021-03-05
Countries
- United States
Study Locations
More Related Trials
-
Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes
NCT03363399 ·Status: COMPLETED
-
Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70
NCT05367583 ·Status: UNKNOWN
-
Collection and Banking of Leukemia Cells MDS/AML
NCT00809367 ·Status: COMPLETED ·Phase: NA
-
Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes.
NCT04399018 ·Status: ACTIVE_NOT_RECRUITING
-
Immunophenotyping of Blast Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From AML and MDS Patients (AML)
NCT03801005 ·Status: COMPLETED
-
Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients
NCT02981615 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
NCT05788679 ·Status: RECRUITING ·Phase: PHASE2
-
Biocollection in MyeloDysplastic Syndrome (P-MDS)
NCT04869683 ·Status: RECRUITING ·Phase: NA
-
Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients
NCT07081087 ·Status: RECRUITING
-
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
NCT00071799 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
NCT04985656 ·Status: WITHDRAWN ·Phase: PHASE2
-
Mean Platelet Volume and Its Relation to Risk Stratification of Myelodysplastic Syndromes
NCT05204953 ·Status: COMPLETED
-
AML-MDS Novel Prognostic Tests Clinical Study
NCT01685619 ·Status: COMPLETED
-
Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia
NCT03697707 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome
NCT01652781 ·Status: UNKNOWN ·Phase: PHASE2
-
Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
NCT04587856 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine
NCT02489929 ·Status: UNKNOWN ·Phase: NA
-
Study on High-risk MDS Patients Based on RNA-seq Technology
NCT03903055 ·Status: UNKNOWN
-
Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT01362140 ·Status: COMPLETED ·Phase: PHASE3
-
Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT00003790 ·Status: COMPLETED
-
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
NCT07270978 ·Status: RECRUITING ·Phase: PHASE1
-
Lifestyle-modifying Interventions in Low-risk MDS Patients
NCT05433805 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome
NCT00217594 ·Status: COMPLETED ·Phase: PHASE2
-
Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples
NCT04251078 ·Status: RECRUITING
-
Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent
NCT03045510 ·Status: UNKNOWN ·Phase: PHASE2